It’s time to rethink clinical trials in a post-pandemic world

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Becky Stephens is more than willing to go to great lengths for a miracle. With a diagnosis of stage 4 colon cancer and chemo treatments that weren’t working, she was desperate for hope—and found it in a clinical trial. 

So, the mother of three started making the often, four-hour round-trip trek from Santa Rosa to UCSF Medical Center every two weeks to participate. But the travel was tough. Aside from the cancer treatment leaving her exhausted, the long car trips were wearing on her. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation
Table of Contents

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login